2025-09-25 - Analysis Report
Okay, here's an analysis of Teladoc Health Inc. (TDOC) based on the data provided.

**Report on Teladoc Health Inc. (TDOC)**

**0. Executive Summary:**

Teladoc Health Inc. (TDOC) is a virtual healthcare company providing telehealth services.  TDOC has significantly underperformed the S&P 500 (VOO). While there has been some recent positive price movement, concerns remain regarding profitability, long-term returns, and analyst sentiment.

**1. Performance vs. S&P 500 (VOO):**

*   **TDOC Cumulative Return:** -54.62%
*   **VOO Cumulative Return:** 71.57%
*   **Absolute Deviation:** -126.19% (TDOC significantly underperformed VOO)
*   **Deviation Range:** Max: 456.6, Min: -170.5, Current: -170.5
*   **Relative Deviation:** 0.0 (Indicates the current deviation is at the lowest end of its historical range)

**Analysis:** TDOC has dramatically underperformed the S&P 500. The relative deviation indicates that the current underperformance is near its worst level historically, suggesting significant investor concerns about the company's prospects.

**Alpha, Beta Analysis:**

| Year       | CAGR      | MDD   | Alpha    | Beta   | Cap(B) |
| :----------- | :-------- | :---- | :------- | :----- | :----- |
| 2015-2017  | 38.0%     | 99.7% | 14.0%    | -0.0   | 6.2    |
| 2016-2018  | 61.0%     | 83.3% | 43.0%    | -0.0   | 8.8    |
| 2017-2019  | 51.0%     | 83.3% | 26.0%    | 0.4    | 14.8   |
| 2018-2020  | 55.0%     | 99.1% | 44.0%    | 0.3    | 35.3   |
| 2019-2021  | -31.0%    | 99.1% | -60.0%   | 0.4    | 16.2   |
| 2020-2022  | -156.0%   | 99.8% | -151.0%  | 0.7    | 4.2    |
| 2021-2023  | -202.0%   | 99.8% | -213.0%  | 0.4    | 3.8    |
| 2022-2024  | -82.0%    | 99.8% | -106.0%  | 0.2    | 1.6    |
| 2023-2025  | -29.0%    | 99.9% | -68.0%   | -1.0   | 1.5    |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Recent CAGR figures are significantly negative, indicating substantial losses for investors over the past several years.
*   **MDD (Maximum Drawdown):** Consistently high MDD values near 100% highlight the extreme volatility and potential for significant losses.
*   **Alpha:** The negative alpha values in recent periods suggest that TDOC has underperformed relative to its risk-adjusted expected return.
*   **Beta:** Beta values fluctuate, with some periods showing negative correlation, which could indicate unique factors affecting TDOC's performance separate from broader market movements.
*   **Cap(B):** The declining market capitalization over the more recent periods reflects the significant value destruction experienced by shareholders.

**2. Recent Price Action:**

*   **Current Price:** 8.415
*   **Last Market Data:** {'price': 8.425, 'previousClose': 8.37, 'change': 0.66} (Slightly positive movement)
*   **5-day Moving Average:** 8.143
*   **20-day Moving Average:** 7.845
*   **60-day Moving Average:** 7.798

**Analysis:** The stock price is above its 5, 20, and 60-day moving averages, suggesting a short-term upward trend. The last market data shows a slight increase, which could be a sign of positive momentum.

**3. Technical Indicators:**

*   **MRI (Market Risk Indicator):** 0.434 (Medium Risk)
*   **RSI (Relative Strength Index):** 63.45 (Approaching overbought territory)
*   **PPO (Percentage Price Oscillator):** 0.7789 (Positive, indicating upward momentum)
*   **Hybrid Signal:** cash_0%_Buy 50% of cash (1 shares - Caution - MRI:0.40)
*   **Delta_Previous_Relative_Divergence (20 days):** 0.0 (Negative - Short-term decline)
*   **Expected Return (%):** -10484.3 (Extremely negative, indicating a high risk of continued underperformance vs S&P 500 over a long term)

**Analysis:** The RSI suggests the stock is nearing overbought territory, implying a potential pullback. The positive PPO supports the recent upward price movement. However, the very negative expected return is a major red flag, suggesting that the stock is highly overvalued or faces severe challenges to its business model. The 'Hybrid Signal' shows a cautious signal. The recent price increase of 0.66 may not be indicative of a sustainable trend.

**4. Recent News & Significant Events:**

*   **Positive Coverage:** Several articles highlight recent price increases (Zacks, StockStory), suggesting some positive short-term sentiment.
*   **Negative Coverage:** Yahoo Finance Video suggests Doximity is a better healthcare stock pick than Teladoc.
*   **Other News:** News about Berkshire Hathaway entering the accident & health market is unlikely to have a direct, significant impact on Teladoc.

**Analysis:** While there's recent positive news regarding the stock's movement, a conflicting opinion suggests alternative investment options, indicating a lack of unanimous positive sentiment.

**4-2. Analyst Opinions:**

*   **Consensus:** Neutral (no specific key provided)
*   **Mean Target Price:** 9.12 (Slightly above current price)
*   **Target Price Range:** 7.00 - 12.00 (Wide range reflects uncertainty)
*   **Recent Rating Changes:** No changes indicated.

**Analysis:** The neutral consensus and wide target price range reflect a lack of strong conviction among analysts regarding the company's future performance.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출      |
| :--------- | :---- | :-------- |
| 2025-07-30 | -0.19 | 0.63 B$   |
| 2025-05-01 | -0.53 | 0.63 B$   |
| 2024-10-31 | -0.19 | 0.64 B$   |
| 2024-08-01 | -4.92 | 0.64 B$   |
| 2025-07-30 | -4.92 | 0.64 B$   |

**Analysis:** TDOC has not been profitable in the analyzed period. EPS is negative and erratic. Revenue has remained relatively stable, but not enough to offset the losses.

**6. Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue   | Profit Margin |
| :----------- | :-------- | :------------ |
| 2025-06-30 | $0.63B    | 69.85%        |
| 2025-03-31 | $0.63B    | 68.73%        |
| 2024-12-31 | $0.64B    | 70.50%        |
| 2024-09-30 | $0.64B    | 71.94%        |
| 2024-06-30 | $0.64B    | 70.73%        |

Capital and Profitability:

| Quarter      | Equity    | ROE       |
| :----------- | :-------- | :-------- |
| 2025-06-30 | $1.42B    | -2.30%    |
| 2025-03-31 | $1.43B    | -6.52%    |
| 2024-12-31 | $1.49B    | -3.25%    |
| 2024-09-30 | $1.51B    | -2.21%    |
| 2024-06-30 | $1.50B    | -55.77%   |

**Analysis:** Revenue is relatively stable. However, the profit margin isn't translating to positive ROE (Return on Equity). Negative ROE values indicate that the company is not generating profits from shareholders' investments. Equity is also declining.

**7. Overall Summary:**

Teladoc Health Inc. (TDOC) faces significant challenges:

*   **Poor Historical Performance:** TDOC has dramatically underperformed the S&P 500, and its historical returns and MDD figures are concerning.
*   **Lack of Profitability:** The company consistently reports negative EPS and ROE, raising questions about its long-term sustainability.
*   **Mixed Sentiment:** While there has been recent positive price movement and some positive news coverage, analyst sentiment remains neutral, and alternative investment options are being suggested.
*   **Technical Concerns:** The RSI is approaching overbought territory, and the extremely negative expected return raises serious red flags about the company's future prospects.

**Conclusion:**

Based on the provided information, investing in TDOC carries a high degree of risk. While there may be short-term trading opportunities, the company's lack of profitability, poor historical performance relative to the market, and negative long-term outlook warrant caution. Investors should carefully consider these factors before investing in TDOC.
